Current management of esophageal cancer - PubMed (original) (raw)
Review
Current management of esophageal cancer
Xavier Benoit D'Journo et al. J Thorac Dis. 2014 May.
Abstract
Management of esophageal cancer has evolved since the two last decades. Esophagectomy remains the primary treatment for early stage esophageal cancer although its specific role in superficial cancers is still under debate since the development of endoscopic mucosal treatment. To date, there is strong evidence to consider that locally advanced cancers should be recommended for a multimodal treatment with a neoadjuvant chemotherapy or a combined chemoradiotherapy (CRT) followed by surgery. For locally advanced squamous cell carcinoma or for a part of adenocarcinoma, some centers have proposed treating with definitive CRT to avoid related-mortality of surgery. In case of persistent or recurrent disease, a salvage esophagectomy remains a possible option but this procedure is associated with higher levels of perioperative morbidity and mortality. Despite the debate over what constitutes the best surgical approach (transthoracic versus transhiatal), the current question is if a minimally procedure could reduce the periopertive morbidity and mortality without jeopardizing the oncological results of surgery. Since the last decade, minimally invasive esophagectomy (MIE) or hybrid operations are being done in up to 30% of procedures internationally. There are some consistent data that MIE could decrease the incidence of the respiratory complications and decrease the length of hospital-stay. Nowadays, oncologic outcomes appear equivalent between open and minimally invasive procedures but numerous phase III trials are ongoing.
Keywords: Esophagectomy; esophageal cancer; minimally invasive esophagectomy (MIE); mucosectomy; neoadjuvant therapy.
Similar articles
- CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0) (NCT03001596).
Tang H, Tan L, Shen Y, Wang H, Lin M, Feng M, Xu S, Guo W, Qian C, Liu T, Zeng Z, Hou Y, Yu Z, Jiang H, Li Z, Chen C, Lian C, Du M, Li H, Xie D, Yin J, Zhao N, Wang Q. Tang H, et al. BMC Cancer. 2017 Jun 28;17(1):450. doi: 10.1186/s12885-017-3446-7. BMC Cancer. 2017. PMID: 28659128 Free PMC article. Clinical Trial. - Evolution in surgical management of esophageal cancer.
Low DE. Low DE. Dig Dis. 2013;31(1):21-9. doi: 10.1159/000343650. Epub 2013 Jun 17. Dig Dis. 2013. PMID: 23797119 Review. - Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After Neoadjuvant Therapy.
Tapias LF, Mathisen DJ, Wright CD, Wain JC, Gaissert HA, Muniappan A, Lanuti M, Donahue DM, Morse CR. Tapias LF, et al. Ann Thorac Surg. 2016 Mar;101(3):1097-103. doi: 10.1016/j.athoracsur.2015.09.062. Epub 2015 Dec 1. Ann Thorac Surg. 2016. PMID: 26652140 - Anastomosis in minimally invasive Ivor Lewis esophagectomy via two ports provides equivalent perioperative outcomes to open.
Zhao Y, Jiao W, Zhao J, Wang X, Luo Y, Wang Y. Zhao Y, et al. Indian J Cancer. 2015 Feb;51 Suppl 2:e25-8. doi: 10.4103/0019-509X.151996. Indian J Cancer. 2015. PMID: 25712837 - Minimally invasive surgery compared to open procedures in esophagectomy for cancer: a systematic review of the literature.
Verhage RJ, Hazebroek EJ, Boone J, Van Hillegersberg R. Verhage RJ, et al. Minerva Chir. 2009 Apr;64(2):135-46. Minerva Chir. 2009. PMID: 19365314 Review.
Cited by
- Impact of enhanced recovery program on patients with esophageal cancer in comparison with traditional care.
Wang L, Zhu C, Ma X, Shen K, Li H, Hu Y, Guo L, Zhang J, Li P. Wang L, et al. Support Care Cancer. 2017 Feb;25(2):381-389. doi: 10.1007/s00520-016-3410-0. Epub 2016 Oct 10. Support Care Cancer. 2017. PMID: 27726032 - Rhizoma Paridis Saponins Suppresses Tumor Growth in a Rat Model of N-Nitrosomethylbenzylamine-Induced Esophageal Cancer by Inhibiting Cyclooxygenases-2 Pathway.
Yan S, Tian S, Kang Q, Xia Y, Li C, Chen Q, Zhang S, Li Z. Yan S, et al. PLoS One. 2015 Jul 6;10(7):e0131560. doi: 10.1371/journal.pone.0131560. eCollection 2015. PLoS One. 2015. PMID: 26147856 Free PMC article. - Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities.
Jiao R, Luo H, Xu W, Ge H. Jiao R, et al. Onco Targets Ther. 2019 Jul 29;12:6023-6032. doi: 10.2147/OTT.S214579. eCollection 2019. Onco Targets Ther. 2019. PMID: 31551657 Free PMC article. - Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC).
Yang PW, Liu YC, Chang YH, Lin CC, Huang PM, Hua KT, Lee JM, Hsieh MS. Yang PW, et al. Front Oncol. 2019 Nov 6;9:1138. doi: 10.3389/fonc.2019.01138. eCollection 2019. Front Oncol. 2019. PMID: 31781483 Free PMC article. - Overexpression of zinc finger E-box binding homeobox factor 1 promotes tumor invasiveness and confers unfavorable prognosis in esophageal squamous cell carcinoma.
Yang X, Wang Q, Dai W, Zhang J, Chen X. Yang X, et al. Tumour Biol. 2014 Dec;35(12):11977-84. doi: 10.1007/s13277-014-2494-8. Epub 2014 Aug 21. Tumour Biol. 2014. PMID: 25142232
References
- Falk GW. Risk factors for esophageal cancer development. Surg Oncol Clin N Am 2009;18:469-85 - PubMed
- Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-34 - PubMed
- Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-92 - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials